Astellas Pharma: Presentation materials for the briefing session (1st quarter of fiscal year 2024).
Astellas Pharma: Financial results (Q1/Fiscal Year 2024).
Astellas Pharma: Announcements of individual stock volatility in fair value of contingent consideration.
Astellas Pharma: About recording the fair value change of consideration related to conditions.
Astellas Pharma: Earnings conference materials for Q1 of the fiscal year ending March 2025.
Astellas Pharma: Supplemental materials for the first quarter financial statements of March 2025.
Astellas Pharma: Supplementary Documents (Q1 FY2024)
Astellas Pharma: March 2025 first quarter financial results announcement [IFRS] (consolidated)
Astellas Pharma: Astellas Pharma has received a positive opinion from the CHMP regarding the combination of zolbetuximab and chemotherapy in the treatment of advanced gastric and gastrointestinal cancers.
Astellas Pharma: The European index CHMP has adopted a marketing authorization recommendation for Zolbetuximab.
Astellas Pharma: Astellas Pharma has received a positive opinion from the CHMP for the combination of PADCEV and KEYTRUDA as the first-line treatment for advanced bladder cancer.
Astellas Pharma: European index CHMP has adopted a sales approval recommendation for the combination therapy with Pemprolizumab targeting primary treatment of advanced urothelial cancer patients with PADCEV (enfortumab vedotin).
Astellas Pharma: Issuance registration documents (stock certificates, corporate bonds, etc.)
Astellas Pharma: Corporate Governance Report
Astellas Pharma: Report on Corporate Governance - July 4, 2024
Astellas Pharma: Change Report (Stock Certificates Eligible for Special Provisions, etc.)
Astellas Pharma: China's National Medical Products Administration has approved XTANDI (enzalutamide) for metastatic hormone-sensitive prostate cancer.
Astellas Pharma: XTANDI, a prostate cancer treatment, has obtained approval for additional indications in China.
Astellas Pharma: Correction Issuance Registration Form
Astellas Pharma: Extraordinary Report
No Data